25 completed, 11 unknown, 4 terminated, 3 withdrawn. 44 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 44 | Completed 25, Unknown 11, Terminated 4, Withdrawn 3, Recruiting 1 |
| Phase 2 | 14 | Completed 7, Terminated 3, Unknown 2, Recruiting 1, Withdrawn 1 |
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19) ACE2 Chewing Gum, Placebo Chewing Gum - SARS-CoV-2 | Phase 1 / Phase 2 | Withdrawn | University of Pennsylvania | 2025-02-01 | 2025-03-30 | |
| Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) Placebo comparator, PRS CK STORM - SARS-CoV-2, Influenza, Human | Phase 1 / Phase 2 | Recruiting | PEACHES BIOTECH | 50 | 2024-10-02 | 2026-06-10 |
| Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination 30μg dose of LYB002V14, 60μg dose of LYB002V14, placebo - SARS-CoV-2, COVID-19 Vaccine | Phase 1 | Unknown | Guangzhou Patronus Biotech Co., Ltd. | 120 | 2023-12-26 | 2023-12-26 |
| A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) SARS-CoV-2 Bivalent mRNA Vaccine, Saline - SARS-CoV-2 | Phase 1 | Unknown | AIM Vaccine Co., Ltd. | 60 | 2023-08-10 | 2023-11-22 |
| Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa VXCO-100, COVID-19 mRNA vaccine - SARS-CoV, SARS-CoV-2 | Phase 1 | Completed | Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company | 130 | 2023-08-04 | 2024-12-10 |
| Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States VXCO-100 - SARS-CoV, SARS-CoV-2 | Phase 1 | Completed | Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company | 121 | 2023-05-11 | 2024-12-10 |
| Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults Glycovax-002 - SARS-CoV-2 | Phase 1 | Unknown | Glycovax Pharma Inc. | 36 | 2023-04-28 | 2024-09-24 |
| A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 1758 | 2023-04-14 | 2025-12-23 |
| Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants SARS-CoV-2 variant mRNA vaccine low dose, SARS-CoV-2 variant mRNA vaccine high dose - SARS-CoV-2 | Phase 1 | Unknown | AIM Vaccine Co., Ltd. | 144 | 2023-02-01 | 2022-11-01 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old mRNA-1010, mRNA-1345, mRNA-1273.214 - SARS-CoV-2, Influenza | Phase 1 | Completed | ModernaTX, Inc. | 392 | 2022-10-14 | 2024-03-08 |
| Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg) - COVID-19, SARS-CoV-2 | Phase 1 | Completed | GlaxoSmithKline | 185 | 2022-08-12 | 2025-02-21 |
| A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults. 20 μg dose of SYS6006, 30 μg dose of SYS6006, Placebo - SARS-CoV-2 | Phase 1 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 40 | 2022-06-01 | 2023-05-24 |
| A Study of Modified mRNA Vaccines in Healthy Adults mRNA-1273, mRNA-1010, mRNA-1345 - SARS-CoV-2, Seasonal Influenza | Phase 1 | Completed | ModernaTX, Inc. | 308 | 2022-05-24 | 2026-03-12 |
| Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster SARS-CoV-2 mRNA vaccine (RBMRNA-405), CoronaVac® - SARS-CoV-2 | Phase 1 | Completed | Argorna Pharmaceuticals Co., LTD | 60 | 2022-05-16 | 2024-03-25 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old mRNA-1073, mRNA-1010, mRNA-1273 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 550 | 2022-05-13 | 2024-02-28 |
| A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years. 20 μg dose of SYS6006, 30 μg dose of SYS6006, Placebo - SARS-CoV-2 | Phase 1 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 40 | 2022-04-27 | 2023-05-24 |
| Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19 COVI-VAC - COVID-19, SARS-CoV-2 | Phase 1 | Completed | Codagenix, Inc | 20 | 2022-04-14 | 2023-01-13 |
| Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59), SARS-CoV-2 beta variant RBD mRNA vaccine, Normal Saline - SARS-CoV-2 | Phase 1 | Completed | University of Melbourne | 76 | 2022-04-05 | 2023-05-15 |
| Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg) - COVID-19, SARS-CoV-2 | Phase 1 | Completed | GlaxoSmithKline | 99 | 2022-03-24 | 2024-08-12 |
| AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics AZD7442 - SARS-CoV-2 | Phase 1 | Completed | AstraZeneca | 46 | 2022-03-21 | 2025-04-18 |
Showing 20 of 44. Sign in to see all of them.
COVID-19 (26) · Coronavirus Infections (10) · Influenza, Human (5) · Virus Diseases (5) · Severe Acute Respiratory Syndrome (3) · Respiratory Distress Syndrome (2) · Acquired Immunodeficiency Syndrome (1) · Cytokine Release Syndrome (1) · Cytomegalovirus Infections (1) · Hypoxia (1) · Lung Diseases (1) · Pneumonia (1) · Respiratory Syncytial Virus Infections (1) · Systemic Inflammatory Response Syndrome (1)
Infections (28) · RNA Virus Infections (28) · Respiratory Tract Diseases (28) · Respiratory Tract Infections (28) · Coronaviridae Infections (27) · Nidovirales Infections (27) · Pneumonia, Viral (26) · Lung Diseases (25) · Pneumonia (25) · Virus Diseases (23) · Coronavirus Infections (17) · Orthomyxoviridae Infections (5) · Pathological Conditions, Signs and Symptoms (2) · Respiration Disorders (2) · Blood-Borne Infections (1)
2019-nCoV Vaccine mRNA-1273 (4) · Saline Solution (4) · Sodium Chloride (4) · CVnCoV COVID-19 vaccine (3) · mRNA-1010 influenza vaccine (3) · GX-19N vaccine (2) · mRNA-1345 respiratory syncytial virus vaccine (2) · ADM03820 (1) · BNT162 Vaccine (1) · Baiya SARS-CoV-2 VAX COVID-19 vaccine (1) · Blood Specimen Collection (1) · COVI-VAC (1) · CV0501 COVID-19 vaccine (1) · Capsules (1) · GLS-5310 vaccine (1)
ModernaTX, Inc. (5) · Genexine, Inc. (3) · AIM Vaccine Co., Ltd. (2) · Argorna Pharmaceuticals Co., LTD (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · GlaxoSmithKline (2) · Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company (2) · Alachua Government Services, Inc. (1) · Arcturus Therapeutics, Inc. (1) · AstraZeneca (1) · BioNTech SE (1) · Codagenix, Inc (1) · CureVac (1) · Entos Pharmaceuticals Inc. (1) · GeneOne Life Science, Inc. (1)
United States (17) · China (7) · South Korea (5) · Australia (4) · South Africa (3) · United Kingdom (3) · Belgium (2) · Brazil (2) · Germany (2) · Burkina Faso (1) · Canada (1) · Israel (1) · Pakistan (1) · Philippines (1) · Russia (1)
Guiling Chen (2) · Jun Yong Choi, MD (2) · JungWon Woo, Ph.D. (2) · Lanjuan Li (2) · Xiang Lu (2) · Yuwen Su (2) · Angela Branche, MD (1) · Anusha Nana, BPharm (1) · Artem A. Shiryaev, Ph.D. (1) · David Bernal, Dr. (1) · Elizabeth Martin, DO (1) · Glenda Gray, MBChB, FC (1)
PMID 33568226, PMID 34473343, PMID 35045888, PMID 35156068, PMID 35454123, PMID 35771353, PMID 36314106, PMID 36851196, PMID 37074202, PMID 38016322, PMID 39481241, PMID 39667115, PMID 40102593, PMID 40276503, PMID 41398408, PMID 41535296, PMID 41627968, PMID 41882056, PMID 42378814
2023 (1)